Your gift is 100% tax deductible
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They can’t tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.
Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they can’t predict what will happen in any particular person’s case. These statistics can be confusing and may lead you to have more questions. Ask your doctor how these numbers might apply to you.
A relative survival rate compares people with the same type and stage of uterine sarcoma to people in the overall population. For example, if the 5-year relative survival rate for a specific stage of uterine sarcoma is 90%, it means that people who have that cancer are, on average, about 90% as likely as people who don’t have that cancer to live for at least 5 years after being diagnosed.
The American Cancer Society relies on information from the Surveillance, Epidemiology, and End Results (SEER) database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.
The SEER database tracks 5-year relative survival rates for uterine sarcoma in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by FIGO or AJCC TNM stages (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:
These numbers are based on women diagnosed with uterine sarcoma between 2012 and 2018. These survival rates differ based on type of uterine sarcoma (leiomyosarcoma, undifferentiated sarcoma, endometrial stromal sarcoma - low grade).
SEER* Stage |
5-Year Relative Survival Rate |
Localized |
60% |
Regional |
37% |
Distant |
12% |
All SEER stages combined | 38% |
SEER* Stage |
5-Year Relative Survival Rate |
Localized |
71% |
Regional |
37% |
Distant |
18% |
All SEER stages combined | 43% |
SEER* Stage |
5-Year Relative Survival Rate |
Localized |
>99.5% |
Regional |
94% |
Distant |
80% |
All SEER stages combined | 96% |
*The outlook for high-grade endometrial stromal sarcoma tends to be much worse than for low-grade endometrial stromal sarcoma, and is more likely to be similar to that for undifferentiated sarcoma (see table above).
*SEER=Surveillance, Epidemiology, and End Results
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Gaillard S and Secord AA. Staging, treatment, and prognosis of endometrial stromal sarcoma and related tumors and uterine adenosarcoma. In: Chakrabarti A and Vora SR, eds. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Accessed June 7, 2022.
Hensley ML and Leitao MM. Treatment and prognosis of uterine leiomyosarcoma. In: Chakrabarti A and Vora SR, eds. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Accessed June 7, 2022.
SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. Accessed at https://seer.cancer.gov/explorer/ on February 23, 2023.
Last Revised: March 1, 2023
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.